Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (74)	6/9/2004 8:22:52 PM
From: Ian@SI	Respond to of 802

Zeta, 1. RAGL = Regards and Good Luck. 2. If you haven't run across CTIC in your very early but potentially dramatic Pancreatic cancer treatments, look at their recent press releases. In a Ph 1 for one of the products (PR released during the past week), several Pancreatic patients showed a response (I believe at least one was a complete response, but my memory sometimes plays nasty little tricks on me). I got the impression that they were probably going to target other cancers first, but this sounded rather striking to me given that it was only a Ph1, and that Pancreatic cancer just doesn't seem to be responsive to any current treatment. Best wishes, Ian

To: zeta1961 who wrote (74)	6/10/2004 12:18:47 AM
From: Jibacoa	Read Replies (1) \| Respond to of 802

Zeta: Ian already answered your question about RAGL.<g> ( I have been running a few "scans" and watching TV and had not checked messages.) Re: The "hemorrhaging in INGN..." lets hope that it will find support above the $5 level. You may remember that in June last year after the first spike to the $10.16 level, the correction the following week brought the price down to $4.80 It then found support at the $5 to $5.30 level and was able to rally to the $11.24 level by mid-September. bigcharts.marketwatch.com INGN has been having pretty good announcements and I still hope that their Advexin and INGN-241 will eventually be approved, but it seems that in spite of the fact that Advexin has received FDA "Fast Track" designation and has been designated as an Orphan Drug under the Orphan Drug Act for head and neck cancer,it will be some time before we see the results of the present PIIIs going on. The estimated loss for the current fiscal year is around $25M and $24.45M for 2005.INGN reportedly has around $30.74M in cash (about $1.16/share)and will need some cash infusion in the near future. RAGL Bernard